Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foscan photodynamic therapy for unresectable perihilar bile duct carcinoma
NL-OMON35016Phase 2Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2010
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temoporfin in cholangiocarcinoma (CCA), sponsored by Amsterdam University Medical Center. Primary endpoints: Rate of local response and Depth of tumoricidal tissue penetration. Planned start Mar 2010; status: not yet recruiting.
02
Drugs
temoporfin
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NL-OMON35016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35016.